Accountable Care Organizations: What's the Impact on the US Pharma Market?

Dublin, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/55tthv/accountable_care) has announced the addition of the "Accountable Care Organizations: What Impact on Pharma?" report to their offering.

ACOs are new healthcare system entities in the US and there is a lot of uncertainty and lack of understanding of how they work, how they differ from the traditional provider-payer relationships and their impact on the pharma market. This report analyzes of the current ACO space, different types of ACOs and their impact on the healthcare and pharma landscape so far.

What's included in this report:

- An overview of the ACO landscape including their reimbursement, structure, priorities and fit with other alternative payment models
- Detailed analysis of the evolving role of medication management within ACOs and likely impact on the pharmaceutical market
- An analysis of how pharma companies' strategies are changing in order to engage with ACOs
- Insights from interviews or correspondence with 15 experts and/or stakeholders in the US reimbursement systems

Key questions answered

- What impact have ACOs had on the US pharmaceutical market so far and how will that change in the future?
- What impact will ACOs have on your company's sales and competitive position?
- What strategies for pharma-ACO engagement will be most successful?

Key Topics Covered:

1. Executive Summary
- Affordable care, accountable care: should pharma care?
- ACOs come in many shapes and sizes
- ACOs, pharma, and medication management
- ACO results so far

2. Affordable Care, Accountable Care: Should Pharma Care?
- Payment reform: from volume to value
- Maturing, multiplying ACOs matter to pharma
- Key terms and players in value-based care
- Bibliography

3. ACOS Come in Many Shapes and Sizes
- ACOs vary in structure, size, culture, and risk
- Variations on the ACO theme
- Winners and losers in a shifting, consolidating provider landscape
- Physician-led ACOs considered best for care, with health plan support
- Bibliography

4. ACOS, Pharma, and Medication Management
- Medication management is not a priority for most ACOs
- Some Medicare ACOs may be using more drugs
- Commercial ACOs' focus on short-term savings means drug cost caps
- Changing roles and incentives for physicians
- More formulary power to providers
- ACO-pharma contracting? Not yet, but soon
- Pharmacists as the new physicians?
- Barriers to promoting pharmacists
- Pharma can help ACOs in other ways: data, education, and patient support
- Bibliography

5. ACO Results So Far
- Savings are modest
- Case study analysis: ACO success stories
- Bibliography

6. Appendix

For more information visit http://www.researchandmarkets.com/research/55tthv/accountable_care

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Healthcare and Medical Devices